EBITDA Margin (Quarterly)

EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues

BioNexus Gene Lab Corp. (BGLC) EBITDA Margin data is not available.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$0.08M
Net Income	$-0.29M
Cost of Goods Sold	$0.06M
Gross Profit	$0.01M
Operating Expenses	$0.36M
Operating Income	$-0.28M
Non-Operating Income/Expense	$-0.00M
Pre-Tax Income	$-0.29M
Normalized Pre-Tax Income	$-0.29M
Income after Taxes	$-0.29M
Income from Continuous Operations	$-0.29M
Consolidated Net Income/Loss	$-0.29M
Normalized Income after Taxes	$-0.29M
EBIT	$-0.26M
EBITDA	$-0.22M
Weighted-Average Shares Outstanding (Basic)	2.42M
Weighted-Average Shares Outstanding (Diluted)	2.42M
Earnings per Share (EPS) (Basic)	$-0.12
Earnings per Share (EPS) (Diluted)	$-0.12
Balance Sheet Financials
Current Assets	$4.94M
Property, Plant, and Equipment	$1.54M
Long-Term Assets	$3.78M
Total Assets	$8.73M
Current Liabilities	$0.81M
Long-Term Debt	$0.05M
Long-Term Liabilities	$0.14M
Total Liabilities	$0.95M
Common Equity	$7.78M
Tangible Shareholders Equity	$7.78M
Shareholders Equity	$7.78M
Common Shares Outstanding	2.42M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-0.57M
Cash Flow from Investing Activities	$0.40M
Cash Flow from Financial Activities	$0.07M
Beginning Cash	$2.49M
End Cash	$2.39M
Increase/Decrease in Cash	$-0.09M
Stock-Based Compensation	--
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	6.08
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.01
Debt to Equity Ratio	0.01
Gross Margin	17.05%
Operating Margin	-370.81%
EBIT Margin	-343.00%
EBITDA Margin	--
Pre-Tax Profit Margin	-376.14%
Profit Margin	-376.14%
Free Cash Flow	$-0.57M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.01
Inventory Turnover	0.10
Receiveable Turnover	0.41
Days Sales in Receivables	219.40
Return on Equity	-3.68%
Return on Tangible Equity	-3.68%
Return on Assets	-3.28%
Return on Investments	-3.66%
Book Value Per Share	$3.22
Free Cash Flow per Share	$-0.24
Operating Cash Flow per Share	$-0.24

Data from Zacks Investment Research, Inc.